All In Biotech

Drug Trial Radar · NCT07723833

A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

A Phase I, Randomized, Single-dose, Crossover, 2-Period, Open-Label Study to Assess the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

152

Planned (sponsor's estimate)

Start

Jul 27, 2026

Primary completion

Nov 18, 2026

Study completion Nov 18, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.

Conditions

  • Healthy Participants

Interventions

  • Elecoglipron Reference Formulation Dose ADrug

    Elecoglipron tablets will be administered orally.

  • Elecoglipron Test formulation 1 Dose ADrug

    Elecoglipron tablets will be administered orally.

  • Elecoglipron Reference Formulation Dose BDrug

    Elecoglipron tablets will be administered orally.

  • Elecoglipron Test formulation 1 Dose BDrug

    Elecoglipron tablets will be administered orally.

  • Elecoglipron Test formulation 2 Dose ADrug

    Elecoglipron tablets will be administered orally.

  • Elecoglipron Test formulation 2 Dose BDrug

    Elecoglipron tablets will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed drug concentration (Cmax)Time frame: At pre-defined intervals from Day 1 to Day 15
  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)Time frame: At pre-defined intervals from Day 1 to Day 15
  3. Area under concentration-time curve from time 0 to infinity (AUCinf)Time frame: At pre-defined intervals from Day 1 to Day 15
  4. Time to reach maximum observed concentration (tmax)Time frame: At pre-defined intervals from Day 1 to Day 15
  5. Terminal elimination rate constant (λz)Time frame: At pre-defined intervals from Day 1 to Day 15
  6. Terminal elimination half-life (t1/2λz)Time frame: At pre-defined intervals from Day 1 to Day 15
  7. Apparent total body clearance (CL/F)Time frame: At pre-defined intervals from Day 1 to Day 15
  8. Apparent volume of distribution based on the terminal phase (Vz/F)Time frame: At pre-defined intervals from Day 1 to Day 15
  9. Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on AUCinf (R AUCinf)Time frame: At pre-defined intervals from Day 1 to Day 15
  10. Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on AUClast (R AUClast)Time frame: At pre-defined intervals from Day 1 to Day 15
  11. Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on Cmax (R Cmax)Time frame: At pre-defined intervals from Day 1 to Day 15

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Glendale, California · Recruiting

  • Research Site

    Brooklyn, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.